Official Title A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission

Purpose

The purpose of this study is to evaluate the safety and efficacy of combination bNAbs in addition to ART initiated during acute HIV infection and to evaluate the impact on HIV viral reservoirs.

Could this study be right for you?

• Newly diagnosed HIV+ individuals who have not yet started antiretroviral therapy (ART)
• Willingness to start ART at enrollment
• Ability and willingness to participate in scheduled study visits and analytic treatment interruption (ATI)
• Weight <115kg

Age Range

18 - 70 years

Official Title An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons Living with HIV

Purpose

This study will evaluate the safety & efficacy of pramipexole vs. escitalopram for treatment of major depressive disorder (MDD) and comorbid MDD/mild neurocognitive disorder (MND) in people living with HIV.

Could this study be right for you?

• People living with HIV ages 18-70
• Diagnosis of MDD alone or with comorbid MDD/MND
• On ART for at least 3 months with HIV RNA <200 copies within 90 days

Age Range

18 - 70 years

Official Title A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1

Purpose

This study will evaluate the safety and efficacy of these treatments in individuals with HIV-1 who started suppressive antiretroviral therapy (ART) during acute HIV-1 infection. The study consists of four steps including an analytical treatment interruption (ATI).

Could this study be right for you?

• Individuals with HIV who started treatment during acute HIV infection
• No known ART interruption >14 consecutive days since ART initiation
• Willingness to participate in analytic treatment interruption
• CD4 count ≥500 within 60 days to study entry
• HIV RNA <50 since initial viral suppression on ART and for at least 1 year prior to study entry

Age Range

18 years and up

Official Title Ohio Mood Disorder Registry and Repository

Purpose

Mood disorders like Major Depressive Disorder and Bipolar Disorder can be chronic, recurrent illnesses. Our treatments to date can help many people but are often trial and error, and continuity and access to care form major barriers. Our purpose is to create a research registry and repository of individuals with mood disorders who are willing to provide clinical data yearly, and who are willing to be contacted to participate in current and future studies of mood disorders.

Could this study be right for you?

Inclusion Criteria

• 8-70 years of age.
• Fluency or advanced conversational English abilities, by self-report.
• Eligible individuals will have a history of two or more mood disorder episodes (depression events of at least 2 weeks meeting 5 of the criteria for major depressive disorder).

Exclusion Criteria

• Head injury with loss of consciousness of five minutes or greater.
• Hospitalization for drug-related concerns.
• Evidence of intellectual disability.
• Diagnosis of a developmental condition like autism spectrum disorder.
• Evidence of psychosis outside of a mood episode (e.g., schizophrenia).
• Hospitalization or infusion for eating condition.

Age Range

8 - 70 years

Official Title A Single-Stage, Adaptive, Open-Label Dose Escalation Safety Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MR- guided Infusion into the Midbrain in Pediatric Patients with AADC Deficiency

Purpose

The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency, and to see if there is a demonstration of effective restoration of AADC function by assays of CSF neurotransmitter metabolites and F-DOPA PET imaging, as allowed by subject’s ability to travel to undergo follow-up visits.

Could this study be right for you?

Inclusion Criteria

• Diagnosis of AADC deficiency from genetic test and CSF/blood enzyme test
• Failed to derive adequate benefit from standard medical therapy as judged by presence of residual oculugyric crises and developmental delay.
• Documented history of motor developmental delay, with inability to walk independently without support by age 18 months.
• Both parents (or legal guardians) must give their consent for their child’s participation in the study unless (i.) one parent is deceased, unknown or incompetent; (ii.) one parent is not reasonably available; or (iii.) one parent has responsibility for the care and custody of the child.

Inclusion Criteria varies, please contact Study Coordinator for more information.

Exclusion Criteria

• Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
• Previous stereotactic neurosurgery.
• Coagulopathy, or need for ongoing anticoagulant therapy.
• Receipt of any investigational agent within 60 days prior to Baseline and during study participation.

Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

2 years and up

Official Title Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

Purpose

The purpose of this study is to determine whether spinal cord stimulation (SCS) will reduce pain in patients with painful Diabetic Peripheral Neuropathy (DPN).

Could this study be right for you?

Inclusion Criteria:

• Over 18 years old
• Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic
• Diagnosis of medically refractory pain secondary to diabetic neuropathy
• Presence of pain for 12 months

Exclusion Criteria:

• Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention
• Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement
• Coagulopathy that cannot be corrected
• Unable to discontinue blood thinning medications

Inclusion and Exclusion Criteria varies, please contact Study Coordinator.

Age Range

18 years and up

Official Title Concurrent optical and magnetic stimulation (COMS) for treatment of refractory diabetic foot ulcer; a prospective randomized, sham-controlled, double-blinded, pivotal clinical trial

Purpose

The purpose of this study is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). 

The duration of this study will last up to 28 weeks. 

Could this study be right for you?

Inclusion

• Male and females aged 22 to 90 years old 
• Able to understand and sign the informed consent form (ICF) and comply with requirements set in the protocol including trial visits, trial treatment and dressing regimens and compliance with required offloading device (if applicable)
• Type 1 or Type 2 diabetes mellitus

Exclusion

• Known pregnancy or lactating
• Active skin cancer, a history of skin cancer or any other localized cancer, precancerous lesions or large moles in the areas to be treated
   

Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

22 - 90 years

Official Title An open-label clinical trial evaluating the ExAblate Model 4000 Type-1 focused ultrasound unilateral thalamotomy for patients with treatment-refractory focal onset epilepsy and comorbid anxiety

Purpose

The purpose of the study is to learn more about whether an ultrasound treatment for epilepsy and anxiety is safe and effective.

Could this study be right for you?

• Age: 18-65 years old
• Treatment resistant Epilepsy (focal or partial-onset seizures)
• ≥ 3 seizures/month
• Moderate-to-severe Anxiety

 

 

Age Range

18 - 65 years

Official Title Strategies to Augment Ketosis- Variations in Ketone Metabolism

Purpose

This study is being done to see how individuals respond to a ketone ester (KE) across different age groups and health statuses. With the ketogenic diet becoming more popular, research on ketones (a molecule created when fat is broken down in the body) has grown as well. 

These findings will be used to help develop future research studies and help others to pick the right doses of ketone supplement.

Could this study be right for you?

• Do NOT smoke or have diabetes, liver disease, kidney disease, cardiovascular disease, or any form of endocrine dysfunction
• Have NOT experienced >10% weight loss in the last 6 months
• Do NOT currently consume a low carbohydrate diet
• Do NOT consume alcohol more than 3 drinks/daily or 14 drinks/weekly
• Do NOT suffer from food allergies or gastrointestinal disorders

Age Range

20 - 70 years

Official Title Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction (STAK-Sleep)

Purpose

To examine if drinking a ketone supplement, twice a day, can improve brain, digital shooting, and physical performance during short-term sleep restriction (4 nights, 50% of normal sleep).

Could this study be right for you?

• Healthy
• Age: 18 - 40 years old
• BMI: 20-35 kg/m2
• No diagnosed sleep disorders
• Not consuming a ketogenic diet

Age Range

18 - 40 years

Official Title Ketogenic Intervention in Depression (KIND)

Purpose

The overarching goal of this pilot study is to: (1) demonstrate that a well-formulated KD can be implemented in treatment program for major depression, and (2) test whether such a program results in reductions of symptoms of depression. 

Could this study be right for you?

Inclusion Criteria:

• OSU students (age 18-30 years at the time of enrollment) with confirmed major depressive disorder as determined by SCID-5 diagnosis at baseline testing.
• Currently engaged in counseling and or medication treatment for depression
• Available for a 12-week period and indicate willingness and ability to eat KD foods as prescribed

Exclusion Criteria:

• Disordered eating, as evidenced by meeting criteria for Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Other Specified Eating Disorder, Unspecified Eating Disorder, or Avoidant Restrictive Eating Disorder during the SCID-5 interview at baseline testing.
• Substantial imminent risk of suicide as assessed during the SCID-5 interview.
• Body mass index (BMI) < 20 kg/m2
• Habitual consumption of a structured low-carbohydrate diet in the last 6-months

Exclusion Criteria varies, please contact Study Coordinator.

Age Range

18 - 30 years

Official Title Understanding the Neurodevelopmental Effects of Youth Tackle Football Participation

Purpose

In this study we are aiming to identify risk factors for higher exposure to football-related neurotrauma in youth tackle football players and to determine the effects of football-related neurotrauma exposure on neurodevelopment in children with no previous tackle football participation.

For this specific posting, we are looking for boys ages 8-12 who are non-athletes or athletes who play non-contact sports to serve as control subjects for our fMRI study. 

Could this study be right for you?

We are looking for boys ages 8-12 who are either non-athletes or do not participate in any contact sports.

• Boys must have no metal implanted in the body
• Have no prior history of head trauma
• Have no serious health or mental health diagnoses
• Must not have a fear of enclosed spaces

Age Range

8 - 12 years